Back to companies

PORTFOLIO

Oculis

Oculis focuses on ophthalmic drugs and topical eye drug formulations. Oculis has developed a formulation technology consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug formulation where diseases of the posterior part of the eye can be treated with a simple topical application (i.e., eye drops) instead of injections or implants.

Milestones

Founded: 2017 Invested: 2020

Leadership Team

Riad Sherif

HQ

Lausanne, Switzerland

Earlybird Lead

OUR PORTFOLIO

OUR PORTFOLIO

SIMILAR COMPANIES

SIMILAR COMPANIES

SIMILAR COMPANIES

Meet the companies we’ve backed on their way to creating groundbreaking change.

Meet the companies we’ve backed on their way to creating groundbreaking change.

WE INVEST BECAUSE
WE BELIEVE

Got an idea that could change the world? If you're an early-stage founder with big ambitions, we'd love to hear from you.

Berlin

Münzstraße 23

10178 Berlin

Cologne

Harry-Blum-Platz 2,

D-50678 Cologne

© 2025 Earlybird Venture Capital. All rights reserved.

Berlin

Münzstraße 23

10178 Berlin

Cologne

Harry-Blum-Platz 2,

D-50678 Cologne

© 2025 Earlybird Venture Capital. All rights reserved.

Berlin

Münzstraße 23

10178 Berlin

Cologne

Harry-Blum-Platz 2,

D-50678 Cologne

© 2025 Earlybird Venture Capital. All rights reserved.

Berlin

Münzstraße 23

10178 Berlin

Cologne

Harry-Blum-Platz 2,

D-50678 Cologne

© 2025 Earlybird Venture Capital. All rights reserved.

Berlin

Münzstraße 23

10178 Berlin

Cologne

Harry-Blum-Platz 2,

D-50678 Cologne

© 2025 Earlybird Venture Capital. All rights reserved.